Fu Minyang, Peng Dandan, Lan Tianxia, Wei Yuquan, Wei Xiawei
Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, China.
Acta Pharm Sin B. 2022 Apr;12(4):1740-1760. doi: 10.1016/j.apsb.2022.01.007. Epub 2022 Jan 19.
Connective tissue growth factor (CTGF), a multifunctional protein of the CCN family, regulates cell proliferation, differentiation, adhesion, and a variety of other biological processes. It is involved in the disease-related pathways such as the Hippo pathway, p53 and nuclear factor kappa-B (NF-B) pathways and thus contributes to the developments of inflammation, fibrosis, cancer and other diseases as a downstream effector. Therefore, CTGF might be a potential therapeutic target for treating various diseases. In recent years, the research on the potential of CTGF in the treatment of diseases has also been paid more attention. Several drugs targeting CTGF (monoclonal antibodies FG3149 and FG3019) are being assessed by clinical or preclinical trials and have shown promising outcomes. In this review, the cellular events regulated by CTGF, and the relationships between CTGF and pathogenesis of diseases are systematically summarized. In addition, we highlight the current researches, focusing on the preclinical and clinical trials concerned with CTGF as the therapeutic target.
结缔组织生长因子(CTGF)是CCN家族的一种多功能蛋白,可调节细胞增殖、分化、黏附以及多种其他生物学过程。它参与了如Hippo通路、p53和核因子κB(NF-κB)通路等与疾病相关的信号通路,因此作为下游效应因子,它促进了炎症、纤维化、癌症及其他疾病的发展。所以,CTGF可能是治疗多种疾病的潜在靶点。近年来,关于CTGF在疾病治疗中的潜力研究也受到了更多关注。几种靶向CTGF的药物(单克隆抗体FG3149和FG3019)正在进行临床试验或临床前试验评估,并已显示出有前景的结果。在这篇综述中,系统总结了CTGF调节的细胞事件以及CTGF与疾病发病机制之间的关系。此外,我们重点介绍了当前的研究,着重关注以CTGF作为治疗靶点的临床前和临床试验。